NASDAQ:ARAVAravive Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aravive Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.79 -0.15 (-2.53 %) (As of 04/7/2020 04:00 PM ET) Add Compare Share Today's Range$5.64Now: $5.79▼$6.5950-Day Range$3.50MA: $6.56▼$9.7652-Week Range$3.34Now: $5.79▼$15.62Volume76,379 shsAverage Volume150,527 shsMarket Capitalization$86.94 millionP/E RatioN/ADividend YieldN/ABeta2.4 ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. Its lead candidate is AVB-S6-500, a soluble Fc-fusion protein, which is in Phase 1b/2 clinical trials for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer, and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAravive has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Aravive has a potential upside of 349.1% from its current price of $5.79.Amount of Analyst CoverageAravive has only been the subject of 1 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesAravive has received 80 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAravive has received 78 “underperform” votes. (Add your “underperform” vote.)Community SentimentAravive has received 50.63% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aravive and other stocks. Vote “Outperform” if you believe ARAV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARAV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders39.80% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.87% of the stock of Aravive is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aravive are expected to grow by 4.43% in the coming year, from ($1.58) to ($1.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -3.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAravive has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.73 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARAV Previous Symbol CUSIPN/A CIKN/A Webhttp://www.aravive.com/ Phone936-355-1910Debt Debt-to-Equity Ratio0.11 Current Ratio13.73 Quick Ratio13.73Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.75 million Price / Sales18.30 Cash FlowN/A Price / Cash FlowN/A Book Value$4.71 per share Price / Book1.23Profitability EPS (Most Recent Fiscal Year)($1.57) Net Income$-18,220,000.00 Net MarginsN/A Return on Equity-32.47% Return on Assets-25.70%Miscellaneous Employees14 Outstanding Shares15,016,000Market Cap$86.94 million Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive ARAV News and Ratings via Email Sign-up to receive the latest news and ratings for ARAV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ARAV Rates by TradingView Aravive (NASDAQ:ARAV) Frequently Asked Questions How has Aravive's stock been impacted by COVID-19 (Coronavirus)? Aravive's stock was trading at $4.99 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ARAV stock has increased by 16.0% and is now trading at $5.79. View which stocks have been mosted impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aravive? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aravive. When is Aravive's next earnings date? Aravive is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Aravive. How were Aravive's earnings last quarter? Aravive Inc (NASDAQ:ARAV) announced its quarterly earnings results on Friday, March, 27th. The company reported ($0.35) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.52) by $0.17. View Aravive's earnings history. What price target have analysts set for ARAV? 5 analysts have issued twelve-month target prices for Aravive's stock. Their forecasts range from $15.00 to $31.00. On average, they expect Aravive's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 349.1% from the stock's current price. View analysts' price targets for Aravive. Has Aravive been receiving favorable news coverage? News headlines about ARAV stock have been trending very negative on Tuesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aravive earned a news impact score of -3.3 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAravive. Are investors shorting Aravive? Aravive saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 505,000 shares, an increase of 21.0% from the February 13th total of 417,400 shares. Based on an average trading volume of 205,100 shares, the short-interest ratio is presently 2.5 days. Currently, 5.9% of the shares of the company are short sold. View Aravive's Current Options Chain. Who are some of Aravive's key competitors? Some companies that are related to Aravive include Mirum Pharmaceuticals (MIRM), Calithera Biosciences (CALA), Syndax Pharmaceuticals (SNDX), OrganiGram (OGI), Trillium Therapeutics (TRIL), Puma Biotechnology (PBYI), Axovant Sciences (AXON), Progenics Pharmaceuticals (PGNX), Lannett (LCI), Satsuma Pharmaceuticals (STSA), Urovant Sciences (UROV), Wave Life Sciences (WVE), DURECT (DRRX), Verrica Pharmaceuticals (VRCA) and MacroGenics (MGNX). What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Inovio Pharmaceuticals (INO), Athersys (ATHX), Flexion Therapeutics (FLXN), Gilead Sciences (GILD), Aerie Pharmaceuticals (AERI), DURECT (DRRX), Precision BioSciences (DTIL), Novavax (NVAX), Roku (ROKU) and AIM ImmunoTech (AIM). Who are Aravive's key executives? Aravive's management team includes the following people: Mr. Jay P. Shepard, Pres, CEO & Director (Age 61)Dr. Jeffrey L. Cleland, Co-Founder (Age 54)Dr. Joshua Silverman Ph.D., Co-FounderMr. Vinay Shah, Chief Financial OfficerDr. Gail F. McIntyre, Chief Scientific Officer (Age 56) What is Aravive's stock symbol? Aravive trades on the NASDAQ under the ticker symbol "ARAV." How do I buy shares of Aravive? Shares of ARAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aravive's stock price today? One share of ARAV stock can currently be purchased for approximately $5.79. How big of a company is Aravive? Aravive has a market capitalization of $86.94 million and generates $4.75 million in revenue each year. The company earns $-18,220,000.00 in net income (profit) each year or ($1.57) on an earnings per share basis. Aravive employs 14 workers across the globe. View additional information about Aravive. What is Aravive's official website? The official website for Aravive is http://www.aravive.com/. How can I contact Aravive? Aravive's mailing address is River Oaks Tower3730 Kirby Drive Suite 1200, Houston TX, 77098. The company can be reached via phone at 936-355-1910 or via email at [email protected] This page was last updated on 4/7/2020 by MarketBeat.com StaffFeatured Article: Catch-Up Contributions
